Antioxidant, anti-inflammatory, antiproliferative and antiviral agent. Inhibits LPS-induced iNOS expression via inhibition of IκBα phosphorylation and p65 nuclear translocation (IC50 = 10 nM). Inhibits HIV-1 replication in vitro. Also potently inhibits MKK1 (MEK1) (IC50 = 0.5 nM) and provides neuroprotection by binding to kainate receptors.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|ethanol||9.31||25mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 372.42. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.69 mL||13.43 mL||26.85 mL|
|5 mM||0.54 mL||2.69 mL||5.37 mL|
|10 mM||0.27 mL||1.34 mL||2.69 mL|
|50 mM||0.05 mL||0.27 mL||0.54 mL|
References are publications that support the products' biological activity.
Cho et al (2002) Potent inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by dibenzylbutyrolactone lignans through inhibition of I-κBα phosphorylation and of p65 nuclear translocation. Int.Immunopharmacol. 2 105 PMID: 11789661
Jang et al (2002) Arctigenin protects cultured cortical neurons from glutamate-induced neurodegeneration by binding to kainate receptor. J.Neurosci.Res. 68 233 PMID: 11948668
Schroder et al (1990) Differential in vitro anti-HIV activity of natural lignans. Z.Naturforsch.C. 45 1215 PMID: 1965681
Cho et al (2003) Arctigenin, a potent inhibitor of MKK1, inhibits lipopolysaccharide (LPS)-inducible nitric oxide synthase expression through inhibition of I-κBα phosphorylation and of p65 nuclear translocation. Exp.Biol.Abstr. 152.2 PMID:
If you know of a relevant reference for Arctigenin, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Arctigenin, supplier, inhibitors, IκB, IκBα, IkappaBalpha, phosphorylation, inhibits, MKK1, kainate, receptors, Nuclear, Factor, Kappa, B, Glutamate, Kainate, Receptors, iGluR, Ionotropic, Transcription, Factors, antiviral, NF-kB, NF-kappaB, NF-κB, (-)-Arctigenin, NF-kB/IkB, MEK, Kainate, Receptors, Antivirals, MEK, Tocris Bioscience
2 Citations for Arctigenin
Citations are publications that use Tocris products. Selected citations for Arctigenin include:
Ogungbe et al (2014) (-) Arctigenin and (+) pinoresinol are antagonists of the human thyroid hormone receptor β. J Chem Inf Model 54 3051 PMID: 25383984
Rycaj et al (2016) Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells. Oncotarget 7 14220 PMID: 26871947
Do you know of a great paper that uses Arctigenin from Tocris? If so please let us know.
Reviews for Arctigenin
There are currently no reviews for this product. Be the first to review Arctigenin and earn rewards!
Have you used Arctigenin?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
MAPK Signaling Scientific Review
MAP kinase signaling is integral to the regulation of numerous cellular processes such as proliferation and differentiation, and as a result is an important focus of cancer and immunology research. Updated for 2016, this review discusses the regulation of the MAPK pathway and properties of MAPK cascades. Compounds available from Tocris are listed.